Meeting
2022 ASCO Annual Meeting
Impact of trilaciclib on multilineage chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer: Post-hoc analyses of data from randomized clinical trials.
Authors
Jerome H. Goldschmidt
Blue Ridge Cancer Care, Blacksburg, VA
Jerome H. Goldschmidt , Jared Weiss , Jenny Zhou , Jessie Wang , Joshua A. Young , Esteban Lemus Wirtz , Julio Ruiz , Huan Huang , Lowell L. Hart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03041311, NCT02499770, NCT02514447
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8568)
DOI
10.1200/JCO.2022.40.16_suppl.8568
Abstract #
8568
Poster Bd #
195
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.
First Author: Jared Weiss
Poster
2017 ASCO Annual Meeting
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
First Author: Caio Max S. Rocha Lima
Poster
2023 ASCO Quality Care Symposium
Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: Retrospective analysis of real-world data from Tennessee Oncology.
First Author: L. Johnetta Blakely
Poster
2024 ASCO Annual Meeting
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.
First Author: Heya Batah